ea0037s24.1 | Androgens and disease progression in prostate cancer | ECE2015
Attard Gerhardt
CYP17A1 inhibition with abiraterone is an effective treatment for castration-resistance prostate cancer (CRPC), with significant improvements in survival, radiological progression free survival, pain, skeletal related events and other secondary end-points. However, resistance invariably develops. Due to mineralocorticoid excess, abiraterone is administered with glucocorticoids. Next-generation sequencing of circulating plasma DNA from CRPC offers an opportunity to monitor tumo...